Evidence map›Paper›PMID 37620852›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

The circadian clock circuitry modulates leukemia initiating cell activity in T-cell acute lymphoblastic leukemia.

Emanuele Murgo, Elisabetta De Santis, Francesca Sansico, Valentina Melocchi, Tommaso Colangelo, Costanzo Padovano, Mattia Colucci, Annalucia Carbone, Beatrice Totti, Alireza Basti and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Emanuele Murgo *Department of Medical Sciences, Division of Internal Medicine and Chronobiology Laboratory, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Elisabetta De Santis *Hematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Francesca SansicoHematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Valentina MelocchiCancer Biomarkers Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Tommaso ColangeloCancer Biomarkers Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Costanzo PadovanoHematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Mattia ColucciHematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Annalucia CarboneDepartment of Medical Sciences, Division of Internal Medicine and Chronobiology Laboratory, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Beatrice TottiHematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Alireza BastiInstitute for Systems Medicine, Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, 20457, Germany.
Lisa GottschlichInstitute for Systems Medicine, Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, 20457, Germany.
Angela RelogioInstitute for Systems Medicine, Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, 20457, Germany.
Nazzareno CapitanioDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Fabrizio BianchiCancer Biomarkers Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy.
Gianluigi Mazzoccoli *Department of Medical Sciences, Division of Internal Medicine and Chronobiology Laboratory, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy. g.mazzoccoli@operapadrepio.it.
Vincenzo Giambra *Hematopathology Unit, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, FG, 71013, Italy. v.giambra@operapadrepio.it.ORCID http://orcid.org/0000-0003-2607-2080
Casa Sollievo della Sofferenza · ITMSH Medical School Hamburg – University of Applied Sciences and Medical University · DEHumboldt-Universität zu Berlin · DEUniversity of Foggia · IT

Funding

Worldwide Cancer Research 20-0318
6 · The paper itself

Abstract

backgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, characterized by restricted cellular subsets with asymmetrically enriched leukemia initiating cell (LIC) activity. Nonetheless, it is still unclear which signaling programs promote LIC maintenance and progression.

methodsHere, we evaluated the role of the biological clock in the regulation of the molecular mechanisms and signaling pathways impacting the cellular dynamics in T-ALL through an integrated experimental approach including gene expression profiling of shRNA-modified T-ALL cell lines and Chromatin Immunoprecipitation Sequencing (ChIP-Seq) of leukemic cells. Patient-derived xenograft (PDXs) cell subsets were also genetically manipulated in order to assess the LIC activity modulated by the loss of biological clock in human T-ALL.

resultsWe report that the disruption of the circadian clock circuitry obtained through shRNA-mediated knockdown of CLOCK and BMAL1 genes negatively impacted the growth in vitro as well as the activity in vivo of LIC derived from PDXs after transplantation into immunodeficient recipient mice. Additionally, gene expression data integrated with ChIP-Seq profiles of leukemic cells revealed that the circadian clock directly promotes the expression of genes, such as IL20RB, crucially involved in JAK/STAT signaling, making the T-ALL cells more responsive to Interleukin 20 (IL20).

conclusionTaken together, our data support the concept that the biological clock drives the expression of IL20R prompting JAK/STAT signaling and promoting LIC activity in T-ALL and suggest that the selective targeting of circadian components could be therapeutically relevant for the treatment of T-ALL patients.

Indexed as

Circadian ClocksPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAnimalsDisease Models, AnimalHumansMiceRNA, Small InterferingSignal TransductionT-LymphocytesRNA, Small InterferingBiological clockCircadianFlow cytometryIL20RSTAT3T-ALL

Identifiers

PMID37620852
PMCPMC10464343
OpenAlexW4386120694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.